Article in Journal of bacteriology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Ashley S Weiss *Division of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0009-0008-7162-4829
Jilarie A Santos-Santiago *Department of Microbiology and Immunology, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-1328-0174
Orlaith KeenanDivision of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Alexander B SmithDivision of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Montana KnightDepartment of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Joseph P Zackular *Division of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3228-3055
Rita Tamayo *Department of Microbiology and Immunology, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-3745-3316
Funding
Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infectionU19AI174998 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DREW WEISSMAN · 2023 to 2026
$7.6M
Molecular interactions in the gut microbiota during early life colonization and perturbationR35GM138369 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI Joseph Paul Zackular · 2020 to 2026
$2.7M
Global regulation in Clostridium difficile via phase variation of cyclic diguanylate signalingR01AI143638 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TAMAYO, RITA · 2019 to 2023
$2.5M
Defining the role of enterococci in reshaping Clostridioides difficile infectionR01AI187174 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI Boone M. Prentice, Joseph Paul Zackular · 2025 to 2026
$1.6M
Defining the role of phenotypic heterogeneity in Clostridioides difficile fitnessR01AI188648 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RITA TAMAYO · 2025 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.